The Incidence and the Risk Factors of Nephrocalcinosis in Very Preterm Infants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

171 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-10-01

Study Completion Date

2021-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study aims to assess the incidence and the risk factors of nephrocalcinosis in very preterm infants using patient data collected during hospitalisation at the Neonatology Centre.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Nephrocalcinosis in preterm infants develops as a result of imbalance between the factors promoting or inhibiting formation of kidney stones. It is caused by intensive treatment as well as functional and morphological kidney immaturity. There is a correlation between the prevalence of nephrocalcinosis and low gestational age.

The study aims prospectively to assess the incidence and the risk factors of nephrocalcinosis in very preterm infants less than 32 weeks of gestation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nephrocalcinosis Preterm Infant

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* preterm infants of the gestational age of \<32 weeks;
* parental consent acquired.

Exclusion Criteria

* death before 28 days of age;
* congenital defects;
* no kidney ultrasound results;
* no parental consent.

Minimum Eligible Age

23 Weeks

Maximum Eligible Age

31 Weeks

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Rasa Garunkstiene, PhD

Role: PRINCIPAL_INVESTIGATOR

Vilnius University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Vilnius University, Neonatology Centre

Vilnius, , Lithuania

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Lithuania

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

158200-R-100

Identifier Type: -

Identifier Source: org_study_id